ClinicalTrials.gg
CompletedNCT01673373ARTISANUpdated Nov 20, 2020Results posted

Renal Stent Placement for the Treatment of Renal Artery Stenosis in Patients With Resistant Hypertension

An interventional study of iCAST™ Rx Stent System in Renal Artery Stenosis and Hypertension, Renovascular, sponsored by Atrium Medical Corporation. Completed at 12 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-11-20.

Sponsored by Atrium Medical Corporation · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
68
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies in Renal Artery Obstruction with a site in United States — none open to participants now, none under way, none of them phase 3. Renal Artery Obstruction · United States.

Enrollment
7th of 14
68 · median 64
Started
2012
with 2 others
No phase
3 of 16
none open now
Registered
12th of 16
by date
Lead sponsor
1 of 16
Atrium Medical Corporation

Among the 16 studies in Renal Artery Obstruction with a site in United States, this one is the 7th largest by enrollment of the 14 interventional ones that give a count, is one of 3 that started in 2012, is one of 3 with no phase, and was the 12th registered.

Renal Artery Obstruction

59 studies on the registry are indexed under Renal Artery Obstruction; 10 are open to participants now.

Browse Renal Artery Obstruction studies →

Open to participants now

None of the 16 studies in Renal Artery Obstruction with a site in United States is open now. The open studies under Renal Artery Obstruction, anywhere →

Who these studies take

Of the 7 Renal Artery Obstruction studies recruiting now, 6 set no upper age limit and none stop at 75 or younger; 1 takes children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 16 studies in Renal Artery Obstruction with a site in United States as a file.
02

Study summary

The purpose of this trial is to test how well the iCAST™ RX Stent works in patients diagnosed with atherosclerotic renal artery stenosis and whether or not increased blood flow by the stent will help to control blood pressure.

Read the detailed description

This is a prospective, single-arm, multicenter clinical trial that will take place at up to 25 US/ Outside US (OUS) sites. Primary endpoints have been determined to show the safety, effectiveness, and clinical outcomes of the iCAST™ RX Stent System. Safety and effectiveness will be evaluated based on the primary patency rate at 9-months on a per lesion basis evaluated against a performance goal of published studies with bare-metal stents. The primary clinical endpoint will assess the improvement in Systolic Blood Pressure (SBP) at 9-months as compared to baseline Systolic Blood Pressure.

Eligible subjects will undergo a two-week Medical Documentation Screening period to confirm resistant hypertension (SBP ≥ 155mmHg) while on maximum tolerable doses of ≥ three anti-hypertensive medications from at least three distinct classes of drugs, one of which must be a diuretic.

There must be documented clinical evidence to support likelihood of angiographic findings > 80% whether it is Duplex Ultrasound (DUS), Computed Tomography angiogram (CTa), Magnetic Resonance angiogram (MRa) or other medical evidence. After meeting screening and clinical eligibility criteria, subjects will undergo a baseline assessment for angiographic eligibility. After angiographic documentation of a ≥ 80% renal artery stenosis or Fraction Flow Reserve (FFR) \< 0.8 is confirmed, the subject may be enrolled in the trial by placement of the investigational device.

The 9-month visit will include a follow-up DUS of the target renal artery. If the DUS is non-diagnostic due to an imaging problem, such as overlying bowel gas or body habitus, a second DUS may be attempted. If the DUS is indicative of ≥ 60% stenosis as determined by the core laboratory, or the second DUS remains non-diagnostic, a contrast angiogram will be used to assess the degree of restenosis of the covered stent(s).

Clinical follow-up visits will be required for all enrolled subjects at 30-days, 9-months, 12-months, 24-months, and 36-months. A 6-month and 18-month visit will occur via telephone to collect medication usage and Adverse Events (AEs) only. The 36-month clinic office visit will be required as the final safety visit.

03

Conditions studied

  • Renal Artery Stenosis
  • Hypertension, Renovascular

Keywords

  • Renal Artery Stenosis
  • Renal Artery Obstruction
  • Renovascular Hypertension
  • Resistant Hypertension
  • Renal Revascularization
  • Atherosclerotic Renal Artery Stenosis
  • Atherosclerotic Renal Artery Stenosis (ARAS)
  • Renal Artery Stenosis (RAS)
  • Uncontrolled hypertension
  • Hypertension
  • Systolic blood pressure
  • Blood pressure
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

General Inclusion Criteria:

  1. Age ≥ 18 at the time of .
  2. Subject or subject's legal representative have been informed of the nature of the trial, agrees to participate, and has signed an Institutional Review Board (IRB)/Ethics Committee (EC) approved Informed Consent Form (ICF).
  3. Subjects that have bilateral kidneys or a solitary functioning kidney with Renal Artery Stenosis in at least one kidney and an average Systolic Blood Pressure (SBP) ≥ 155mmHg.
  4. Subject has a history of maximum tolerable dose of ≥ 3 anti-hypertensive medications of different classes, one of which must be a diuretic (for at least two weeks prior to Medical Documentation Screening period).

    a. A documented history for a minimum of 3 months showing reasonable and aggressive efforts to manage hypertension prior to consent. This must include the use of a broad variety of medications that have been used and failed or not tolerated.

  5. Subject must have documented clinical evidence to support likelihood of angiographic findings > 80% whether it is DUS, CTa, MRa or other medical evidence.
  6. (NYHA) class I, II, or III the time of trial enrollment.

Note: When a subject has bilateral Renal Artery Stenosis both of which require stenting, it is recommended to treat both kidneys with an iCAST™ RX Stent System during the index procedure. In the event that a subject needs a renal stenting procedure staged for renal protection, it is important that the Investigator treats the second renal artery with an iCAST™ RX Stent System after 30 days of the index procedure. If subjects with bilateral stenosis have only one lesion that meets protocol inclusion criteria that lesion should be treated per protocol. The recommendation is to NOT treat the second non-qualifying lesion, however if the operator feels strongly it is indicated, then they should treat per standard of care after 30-days post index procedure in order to comply with exclusion criteria #10.

Subjects with flash pulmonary edema are allowed into the trial should they meet all other Inclusion and Exclusion criteria.

Angiographic Anatomic Inclusion Criteria:

  1. Angiographic diameter renal artery stenosis ≥ 80% involving unilateral or bilateral renal arteries.

    a. The degree of percent diameter stenosis for all lesions intended to be treated, must be confirmed via one of the following methods: i. Manual or automated measurement with calipers ii. Measured Flow Fraction Reserve (FFR) \< 0.8 using a pressure wire iii. Measured translesional peak pressure gradient of > 21 mmHg after induced hyperemia via dopamine or papaverine using a 4 Fr or less catheter or pressure wire.

    b. Subjects with 60-79% angiographic stenosis who have confirmed FFR \< 0.8 may be enrolled.

  2. Renal pole-to-pole length > 8cm (per visual estimate).
  3. Target lesion length ≤ 16mm per vessel (per visual estimate).
  4. Renal artery vessel diameter ≥ 5.0mm and ≤ 7.0mm (per visual estimate).
  5. Lesion originating ≤ 15mm of the renal ostium.

General Exclusion Criteria:

  1. Subject's estimated is \< 12 months.
  2. Subject has a history of transplanted kidney(s), has had another recent organ transplant or polycystic kidney disease.
  3. Subject with estimated (eGFR) ≤ 25 mL/min/1.73 m2
  4. Subject has a history of bleeding diathesis or coagulopathy or refuses blood transfusions.
  5. Subject has a known to heparin, aspirin, thienopyridine, other anti-coagulant/antithrombotic therapies, contrast media, stainless steel, and/or polytetrafluoroethylene (PTFE).
  6. Subject has had a previous renal bypass operation, a bypass is planned, or the target lesion is located within or beyond a bypass graft.
  7. Subject has received a thrombolytic agent within the past 30 days.
  8. Subject has documented acute pulmonary edema or systolic heart failure with \< 30% and/or hospitalization requiring intubation and ventilation support for this diagnosis within the previous 90 days or hypertensive emergencies defined as resulting in organ damage.
  9. Concurrent enrollment in any trial wherein subject's participation has not been completed.
  10. Subject has had a planned or anticipated cardiovascular surgical or interventional procedure outside of the affected renal artery (including, but not limited to, aortic, renal, cardiac, carotid, femoro-popliteal, and below the knee) within 30 days prior to the index procedure and prior to completion of the 30 day follow-up.
  11. Subject has suffered a stroke or (TIA) in the past 3 months.
  12. Subject is pregnant, lactating, or is of and plans to become pregnant during the follow-up trial period.
  13. Subject with significant valvular disease.
  14. Subject with known significant proteinuria > 2+ or > 2.0gm/d.
  15. Subject with known bilateral upper-extremity arterial stenosis that result in spuriously low arm pressures or without the ability to gain reliable blood pressure measurements in at least one upper extremity.
  16. Subject with active sepsis.
  17. Subject with serum creatinine ≥ 3.0mg/dL.
  18. Subject with NYHA Class IV at the time of enrollment.
  19. Subject is on hemodialysis.
  20. Subject has a history of renal aneurysm.
  21. Subject with cardiogenic shock.
  22. Subject with cardiomyopathy.
  23. Subject has an uncontrolled concurrent illness, including but not limited to ongoing or active infection or active disease requiring therapy.
  24. Any subject with cardiovascular, respiratory, neurologic, hepatic, endocrine, major systematic disease, making implementation or interpretation of the protocol or protocol results difficult or who in the opinion of the investigator would not be a good candidate for enrollment.

Angiographic Anatomic Exclusion Criteria:

  1. The planned site of intervention is totally occluded or has an anatomic configuration likely to prohibit adequate dilatation, and/or passage or implantation of the investigational device.
  2. Subject has multiple ipsilateral lesions of the target renal artery that cannot be covered by a single stent.
  3. There is a previously implanted stent in the target vessel or there is a previously implanted stent in the contralateral vessel \< one year.
  4. Subject has fibromuscular dysplasia, in renal artery and/or other vascular bed.
  5. The target lesion site is associated with a thrombus.
  6. Target lesion treated with laser atherectomy, directional atherectomy or other adjuncts to percutaneous balloon angioplasty (PTA).
  7. Subject has a critical stenotic (> 70%) small accessory renal artery.
  8. Subject has an abdominal aortic aneurysm > 4.0cm in diameter or a severe atherosclerotic aorta.
  9. Main renal artery length ≤ 15mm precluding the safe deployment of a covered renal stent.
  10. Any lesion that would include blocking of renal artery side branch.
  11. Renal artery stenosis due to dissection of renal artery: spontaneous or traumatic.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
68 participants (actual)

Study arms

  • Experimental
    iCAST RX™ Stent Systen

    All enrolled subjects will receive the iCAST RX™ Stent System

    Device: iCAST™ Rx Stent System

Interventions

  • DeviceiCAST™ Rx Stent System

    All enrolled subjects will undergo primary stenting of the target lesion(s) by placement of the iCAST™ RX Stent System.

    Also known as: iCAST™ RX

06

What researchers measure

Primary outcomes

  1. Primary Patency

    Primary patency rate at 9 months was defined as continuous patency without the occurrence of a total occlusion of the original lesion, without a re-intervention to treat a partial or total occlusion of the stented segment, or bypass of the stented segment due to clinically-driven restenosis or occlusion.

    Time frame: 9 months

  2. Systolic Blood Pressure

    Change in systolic blood pressure (SBP) at 9 months as compared to baseline SBP.

    Time frame: Baseline and 9 months

Secondary outcomes

  1. Procedure-Related Major Adverse Events (MAE)

    The occurence of procedure-related MAEs is reported as a percentage of subjects with MAE. Inclusive of: 1. Procedure- or device-related occurrence of death 2. Q-Wave myocardial infarction (MI) 3. Clinically driven target lesion revascularization (TLR) 4. Significant embolic events defined as unanticipated kidney/bowel infarct, clinically driven by symptoms of abdominal or back pain and confirmed with CT scan or open surgery; lower extremity ulceration or gangrene; or kidney failure.

    Time frame: 30 days, 9 months

  2. Technical Success

    Technical success is defined as successful delivery and deployment of the iCAST™ RX Stent System with ≤ 30% residual angiographic stenosis after covered stent deployment (including post-dilatation) assessed via quantitative vascular analysis (QVA) by an independent core laboratory.

    Time frame: Day of Procedure

  3. Acute Procedural Success

    Acute procedural success is defined as technical success without the occurrence of MAE prior to hospital discharge.

    Time frame: Day of Procedure, prior to hospital discharge

  4. Target Lesion Revascularization (TLR)

    Target Lesion Revascularization (TLR) is measured as the proportion of subjects-lesions that require a clinically-driven reintervention of the target lesion through 9 months. a. A clinically-driven TLR is defined as a TLR (percutaneous balloon angioplasty (PTA), bare metal stent or repeat covered stent deployment, or surgical bypass) due to documented recurrent hypertension from 30-days post-procedure level and/or deterioration in renal function from baseline value, associated with angiographic core laboratory adjudication of a ≥ 60% diameter covered stent restenosis.

    Time frame: 9 months

  5. Rate of Incidental TLR

    The rate of incidental TLR is the rate of TLRs not meeting the definition of a clinically-driven TLR.

    Time frame: 9 months

  6. Systolic Blood Pressure (SBP) Control

    The change in SBP from baseline to 30 days

    Time frame: Baseline and 30 days

  7. SBP Control

    The change in SBP from baseline to 9 months

    Time frame: Baseline and 9 months

  8. Secondary Patency Rate

    Secondary patency rate at 9 months after a clinically-driven TLR which restores patency after total occlusion.

    Time frame: 9 months

  9. Change in Number of Anti-Hypertensive Medications

    Change in number of anti-hypertensive medications as compared to baseline.

    Time frame: Baseline and 9 months

  10. Change in Renal Function

    Renal function compared to baseline as measured by estimated Glomerular Filtration Rate (eGFR) at 30 days.

    Time frame: Baseline and 30 days

  11. Change in Renal Function

    Renal function compared to baseline as measured by estimated Glomerular Filtration Rate (eGFR) at 9 months.

    Time frame: Baseline and 9 months

07

Results

Posted Aug 13, 2019
Limitations and caveats
The limitation of the study was the termination of enrollment due to the change in clinical practice.

Participant flow

Participant flow — Overall Study
MilestoneiCAST™ RX Stent System
Started68
Completed66
Not completed2
Withdrew: Death2

Outcome measures

PrimaryPrimary Patency

Primary patency rate at 9 months was defined as continuous patency without the occurrence of a total occlusion of the original lesion, without a re-intervention to treat a partial or total occlusion of the stented segment, or bypass of the stented segment due to clinically-driven restenosis or occlusion.

Time frame:
9 months
Reported as:
Count of units · Subject-lesions
Primary Patency
Subject-lesionsiCAST™ RX Stent System
Primary Patency66
Statistical analysis
  • iCAST™ RX Stent System · one-sided exact · p = <.0001 (The p-value was computed using a one-sided exact test of the difference between the observed rate and the Performance Goal (equal to 70%). The defined threshold for statistical significance is .025.)
PrimarySystolic Blood Pressure

Change in systolic blood pressure (SBP) at 9 months as compared to baseline SBP.

Time frame:
Baseline and 9 months
Reported as:
Mean · mmHg
Systolic Blood Pressure
mmHgiCAST™ RX Stent System
Systolic Blood Pressure15.7 ± 21.20
Statistical analysis
  • iCAST™ RX Stent System · t-test, 1 sided · p = .0192 (The defined threshold for statistical significance is .025.)
SecondaryProcedure-Related Major Adverse Events (MAE)

The occurence of procedure-related MAEs is reported as a percentage of subjects with MAE. Inclusive of: 1. Procedure- or device-related occurrence of death 2. Q-Wave myocardial infarction (MI) 3. Clinically driven target lesion revascularization (TLR) 4. Significant embolic events defined as unanticipated kidney/bowel infarct, clinically driven by symptoms of abdominal or back pain and confirmed with CT scan or open surgery; lower extremity ulceration or gangrene; or kidney failure.

Time frame:
30 days, 9 months
Reported as:
Count of participants · Participants
Procedure-Related Major Adverse Events (MAE)
ParticipantsiCAST™ RX Stent System
Overall subjects experiencing MAE5
MAE within 30 days0
MAE within 9 months2
SecondaryTechnical Success

Technical success is defined as successful delivery and deployment of the iCAST™ RX Stent System with ≤ 30% residual angiographic stenosis after covered stent deployment (including post-dilatation) assessed via quantitative vascular analysis (QVA) by an independent core laboratory.

Time frame:
Day of Procedure
Reported as:
Count of units · Subject-lesions
Technical Success
Subject-lesionsiCAST™ RX Stent System
Technical Success81
SecondaryAcute Procedural Success

Acute procedural success is defined as technical success without the occurrence of MAE prior to hospital discharge.

Time frame:
Day of Procedure, prior to hospital discharge
Reported as:
Count of units · Subject-lesions
Acute Procedural Success
Subject-lesionsiCAST™ RX Stent System
Acute Procedural Success81
SecondaryTarget Lesion Revascularization (TLR)

Target Lesion Revascularization (TLR) is measured as the proportion of subjects-lesions that require a clinically-driven reintervention of the target lesion through 9 months. a. A clinically-driven TLR is defined as a TLR (percutaneous balloon angioplasty (PTA), bare metal stent or repeat covered stent deployment, or surgical bypass) due to documented recurrent hypertension from 30-days post-procedure level and/or deterioration in renal function from baseline value, associated with angiographic core laboratory adjudication of a ≥ 60% diameter covered stent restenosis.

Time frame:
9 months
Reported as:
Count of units · Subject-lesions
Target Lesion Revascularization (TLR)
Subject-lesionsiCAST™ RX Stent System
Target Lesion Revascularization (TLR)3
SecondaryRate of Incidental TLR

The rate of incidental TLR is the rate of TLRs not meeting the definition of a clinically-driven TLR.

Time frame:
9 months
Reported as:
Count of units · Subject-lesions
Rate of Incidental TLR
Subject-lesionsiCAST™ RX Stent System
Rate of Incidental TLR2
SecondarySystolic Blood Pressure (SBP) Control

The change in SBP from baseline to 30 days

Time frame:
Baseline and 30 days
Reported as:
Mean · mmHg
Systolic Blood Pressure (SBP) Control
mmHgiCAST™ RX Stent System
Systolic Blood Pressure (SBP) Control-13.6 ± 18.83
SecondarySBP Control

The change in SBP from baseline to 9 months

Time frame:
Baseline and 9 months
Reported as:
Mean · mmHg
SBP Control
mmHgiCAST™ RX Stent System
SBP Control-15.7 ± 21.20
SecondarySecondary Patency Rate

Secondary patency rate at 9 months after a clinically-driven TLR which restores patency after total occlusion.

Time frame:
9 months
Reported as:
Count of units · Subject-lesions
Secondary Patency Rate
Subject-lesionsiCAST™ RX Stent System
Secondary Patency Rate3
SecondaryChange in Number of Anti-Hypertensive Medications

Change in number of anti-hypertensive medications as compared to baseline.

Time frame:
Baseline and 9 months
Reported as:
Mean · Number of Anti-hypertensive Medications
Change in Number of Anti-Hypertensive Medications
Number of Anti-hypertensive MedicationsiCAST™ RX Stent System
Change in Number of Anti-Hypertensive Medications-0.1 ± 0.76
SecondaryChange in Renal Function

Renal function compared to baseline as measured by estimated Glomerular Filtration Rate (eGFR) at 30 days.

Time frame:
Baseline and 30 days
Reported as:
Mean · eGFR mL/min/1.73 m^2
Change in Renal Function
eGFR mL/min/1.73 m^2iCAST™ RX Stent System
Change in Renal Function-0.5520 ± 8.42795
SecondaryChange in Renal Function

Renal function compared to baseline as measured by estimated Glomerular Filtration Rate (eGFR) at 9 months.

Time frame:
Baseline and 9 months
Reported as:
Mean · eGFR mL/min/1.73 m^2
Change in Renal Function
eGFR mL/min/1.73 m^2iCAST™ RX Stent System
Change in Renal Function-1.9964 ± 13.42781

Adverse events

Collected over Non-serious Adverse Events were reported through 9 months. Serious Adverse Events were reported through 3 years.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
iCAST™ RX Stent System4/68 (5.9%)40/68 (58.8%)12/68 (17.6%)
Most frequent serious events
Showing 10 of 61
Most frequent serious events
EventiCAST™ RX Stent System
Arterial restenosisInjury, poisoning and procedural complications8/68
Angina pectorisCardiac disorders7/68
Cardiac failure congestiveCardiac disorders6/68
PneumoniaInfections and infestations6/68
ArrhythmiaCardiac disorders5/68
Cerebrovascular accidentNervous system disorders4/68
AnaemiaBlood and lymphatic system disorders3/68
Myocardial infarctionCardiac disorders2/68
Urinary tract infectionInfections and infestations2/68
Renal failure acuteRenal and urinary disorders2/68
Most frequent other events
Most frequent other events
EventiCAST™ RX Stent System
DyspnoeaRespiratory, thoracic and mediastinal disorders5/68
AnaemiaBlood and lymphatic system disorders4/68
Subcutaneous haematomaInjury, poisoning and procedural complications4/68

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)iCAST™ RX Stent System
<=18 years0
Between 18 and 65 years16
>=65 years52
Age, Continuous
Age, Continuous(years)iCAST™ RX Stent System
Mean71.7 ± 10.17
Sex: Female, Male
Sex: Female, Male(Participants)iCAST™ RX Stent System
Female35
Male33
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)iCAST™ RX Stent System
Hispanic or Latino6
Not Hispanic or Latino62
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)iCAST™ RX Stent System
American Indian or Alaska Native1
Asian7
Native Hawaiian or Other Pacific Islander0
Black or African American4
White53
More than one race3
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(Participants)iCAST™ RX Stent System
United States68
Number of Qualifying Lesions
Number of Qualifying Lesions(Participants)iCAST™ RX Stent System
Unilateral54
Bilateral14
Systolic Blood Pressure
Systolic Blood Pressure(mmHg)iCAST™ RX Stent System
Mean166.2 ± 12.19
08

Study locations

12 sites
  • Mission Cardiovascular Research Institute
    Fremont, California 94538, United States
  • Medical Center of the Rockies
    Loveland, Colorado 80538, United States
  • Clearwater Cardiovascular and Interventional Consultants
    Clearwater, Florida 33756, United States
  • Advocate Health and Hospitals Corporation
    Naperville, Illinois 60563, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Beaumont Health Systems
    Royal Oak, Michigan 48073, United States
  • Holy Name Medical Center
    Teaneck, New Jersey 07666, United States
  • Mid Carolina Cardiology
    Charlotte, North Carolina 28204, United States
  • NC Heart and Vascular Research
    Raleigh, North Carolina 27610, United States
  • OhioHealth Research Institute
    Columbus, Ohio 43214, United States
  • Wellmont CVA Heart Institute
    Kingsport, Tennessee 37660, United States
  • Tennova Healthcare - Turkey Creek Medical Center
    Knoxville, Tennessee 37934, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2012 to primary completion in Jun 2018, 68 months.

Results were first posted in Aug 2019, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 23, 2012
First posted
Aug 28, 2012
StartActual
Oct 23, 2012
Primary completionActual
Jun 27, 2018
CompletionActual
Oct 26, 2020
Results first posted
Aug 13, 2019
Last update
Nov 20, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 20, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01673373
Lead sponsor
Atrium Medical Corporation
Responsible party
Sponsor
First posted
Aug 28, 2012
Start date
Oct 23, 2012
Primary completion
Jun 27, 2018
Completion
Oct 26, 2020
Results posted
Aug 13, 2019
Last update
Nov 20, 2020

Study contacts

Ken Rosenfield, MD
principal investigator · Massachusetts General Hospital
Gary Ansel, MD
principal investigator · OhioHealth Research Institute

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion